Antitumor efficacy of intravesical BCG, gemcitabine, interferon-α and interleukin-2 as mono-or combination-therapy for bladder cancer in an orthotopic tumor model

Clinical Medicine Insights: Oncology

Volumn 5, Issue , 2011, Pages 315-323

  Xiao, Zhengwen ^a   Hanel, Erich ^a   Mak, Allan ^a   Moore, Ronald B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

BCG; Bladder cancer; Gemcitabine; Interferon ; Intravesical therapy

Indexed keywords

BCG VACCINE; GEMCITABINE; INTERLEUKIN 2; RECOMBINANT ALPHA INTERFERON; TICE; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPSY; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; EARLY CANCER; FEMALE; IMMUNOCOMPETENCE; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; RAT; TREATMENT DURATION; TUMOR MODEL; UROGENITAL TRACT CANCER;

EID: 80053608900     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S7658     Document Type: Article

References (31)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Altay B, Girgin C, Kefi A, Cikili N. The best management of superficial bladder tumours: comparing TUR alone versus TUR combined with intravesical chemotherapy modalities? Int Urol Nephrol. 2000;32(1):53-8.
3. Amling CL. Diagnosis and management of superficial bladder cancer. Curr Probl Cancer. 2001;25:217-80.
4. Herr HW, Morales A. History of Bacillus Calmette-Guérin and bladder cancer: an immunotherapy success story. J Urol. 2008;179:53-6.
5. Lamm DL. Bacillus Calmette-Guérin immunotherapy for bladder cancer. J Urol. 1985;134:40-7.
6. Herr HW, Warringer DD, Fair WF, Oettgen HF. Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10 year follow-up. J Urol. 1992;147:1020-3.
7. Lamm DL, Griffith JG. Intravesical therapy: does it affect the natural history of superficial bladder cancer? Semin Urol. 1992;10:39-44.
8. Lamm DL. Complications of Bacillus Calmette-Guerin immunotherapy. Urol Clin North Am. 1992;19:565-72.
9. Watanabe E, Matsuyama H, Matsuda K, et al. Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother. 2003;52:481-6.
10. Saint F, Kurth N, Maille P, et al. Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guérin response of superficial bladder cancer during induction course and maintenance therapy. Int J Cancer. 2003;107:434-40.
11. Brandau S, Riemensberger J, Jacobsen M, et al. NK cells are essential for effective BCG immunotherapy. Int J Cancer. 2001;92(5):697-702.
12. Gan YH, Zhang Y, Khoo HE, Esuvaranathan K. Antitumor immunity of Bacillus Calmette-Guerin and interferon alpha in murine bladder cancer. Eur J Cancer. 1999;35:1123-9.
13. Ludwig AT, Moore JM, Luo Y, et al. Tumor necrosis factor-related apoptosisinducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced anti-tumor activity. Cancer Res. 2004;10:3386-90.
14. Simmons MP, Nauseef WM, Griffith TS. Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer. Immunologic Res. 2007;39:79-93.
15. O'Kane HF, Watson CJ, Johnston SR, Petak I, Watson WG, Williamson KE. Targeting death receptors in Bladder, prosatate and renal cancer. J Urol. 2006;175:432-8.
16. O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-α2B plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. J Urol. 2001;166:1300-5.
17. O'Donnell MA, Lilli K, Leopold C, et al. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2B for superficial bladder cancer. J Urol. 2004;172: 888-93.
18. Grossman HB, O'Donnell MA, Cookson MS, Greenberg RE, Keane TE. Bacillus Calmette-Guerin failures and beyond: contemporary management of non-muscle-invasive bladder cancer. Rev Urol. 2008;10:281-9.
19. Horiguchi Y, Larchian WA, Kaplinsky R, Fair WR, Heston WD. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model. Gene Ther. 2000;7:844-51.
20. Moibi J, Mak A, Sun B, Moore RB. Urothelial cancer cell response to combination therapy of gemcitabine and TRAIL. Int J Oncol. 2011;39:61-71.
21. Pauwels B, Vermorken JB, Wouters A, et al. The role of apoptotic cell death in the radiosensitising effect of gemcitabine. Br J Cancer. 2009;101:628-36.
22. Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacillus Calmette-Guerrin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006;24:2729-34.
23. Xiao Z, McCallum TJ, Brown K, et al. Characterization of a novel transplantable orthotopic rat bladder transitional cell tumor model. Br J Cancer. 1999;81:638-46.
24. Asanuma H, Arai T, Seguchi K, et al. Successful diagnosis of orthotopic rat superficial bladder tumor model by ultrathin cystoscopy. J Urol. 2003;169:718-20.
25. Hendricksen K, Molkenboer-Kuenen J, Oosterwijk E, Hulsbergen-van de Kaa CA, Witjes JA. Evaluation of an orthotopic rat bladder urothelial cell carcinoma model by cystoscopy. BJU International. 2008;101:889-93.
26. Hanel EG, Xiao Z, Wong KK, Lee PW, Britten RA, Moore RB. A novel intravesical therapy for superficial bladder cancer in an orthotopic model: oncolytic reovirus therapy. J Urol. 2004;172:2018-22.
27. Soloway MS, Sofer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol. 2002;167:1573-83.
28. Laufer M, Ramalingam S, Schoenberg MP, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: A phase I and pharmacokinetic study. J Clin Oncol. 2003;21:697-703.
29. Xiao Z, Brown K, Tulip J, Moore RB. Whole bladder photodynamic therapy for orthotopic superficial bladder cancer in rats: A study of intravenous and intravesical administration of photosensitizers. J Urol. 2003;169:352-6.
30. Cozzi PJ, Bajorin DF, Tong W, et al. Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. Clin Cancer Res. 1999;5:2629-37.
31. Dalbagni G, Russo P, Sheinfeld J, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol. 2002;20:3193-8.